Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Light blast during brain surgery aims to fry leftover cancer cells

NCT ID NCT04391062

First seen Jan 10, 2026 · Last updated Jun 19, 2026 · Updated 26 times

Summary

This phase 2 trial tested whether increasing the light dose during a special type of therapy called photodynamic therapy (PDT) is safe for people with glioblastoma, an aggressive brain cancer. Fourteen patients received a drug (5-ALA) before surgery, then a red laser was shone on the tumor bed after removal. The goal was to find the highest safe light dose. The treatment was added on top of standard care: surgery, radiation, and chemotherapy.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for GLIOBLASTOMA are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Contacts and locations

Locations

  • Hopital Roger Salengro, CHU Lille

    Lille, 59037, France

  • Hôpital Erasme, Clinique Universitaire de Bruxelles

    Brussels, Belgium

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance

5-aminolevulinic acid (5-ALA) plus red light laser

What this could lead to

If successful, this could point toward a more effective way to destroy leftover cancer cells during brain tumor surgery, potentially delaying recurrence.

What could go wrong

This is a very small, early-phase study with only 14 participants. The main goal is to find a safe light dose, not to prove it works. Risks include brain swelling or damage from the light therapy.

Conditions

The condition(s) this trial relates to.

glioblastoma neoplasm

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.